Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2366456 Target Snapshot

Voltage-dependent L-type calcium channel subunit alpha-1C · SINGLE PROTEIN · Cavia porcellus

186Compounds
112Assays
31Approved Drugs
220.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O35505. Use UniProt O35505 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O35505 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Voltage-dependent L-type calcium channel subunit alpha-1C as ChEMBL target CHEMBL2366456, mapped to UniProt O35505. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Voltage-dependent L-type calcium channel subunit alpha-1C
SINGLE PROTEIN · Cavia porcellus
As of 2026-09-13
ChEMBL target ID
CHEMBL2366456
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O35505
Voltage-dependent L-type calcium channel subunit alpha-1C
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Voltage-dependent L-type calcium channel subunit alpha-1C is the right protein anchor across sources, using UniProt O35505 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelVoltage-dependent L-type calcium channel subunit alpha-1C
UniProt AccessionO35505
Component TypeProtein
Sequence Length2169 aa

Voltage-dependent L-type calcium channel subunit alpha-1C

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Voltage-dependent L-type calcium channel subunit alpha-1C, mapped to UniProt O35505. Sequence length is 2169 aa.

Mapped IDO35505
Review nameVoltage-dependent L-type calcium channel subunit alpha-1C
OrganismCavia porcellus
Clinical Profile

Clinical Phase Distribution

31
Approved
3
Phase III
9
Phase II
Assay Mix

Activity Type Distribution

IC50220.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2237954 10.51 IC50 0.0309 Preclinical
CHEMBL2237953 10.36 IC50 0.04365 Preclinical
CHEMBL2237955 10.34 IC50 0.04571 Preclinical
CHEMBL2261189 10.18 IC50 0.06683 Preclinical
CHEMBL2261183 9.89 IC50 0.13 Preclinical
CHEMBL2261188 9.88 IC50 0.1321 Preclinical
CHEMBL2261191 9.84 IC50 0.1459 Preclinical
CHEMBL2261182 9.8 IC50 0.1581 Preclinical
CHEMBL2237950 9.74 IC50 0.182 Preclinical
CHEMBL2261187 9.67 IC50 0.2118 Preclinical
Distribution

pChEMBL Value Distribution

22
5.0
24
5.5
23
6.0
13
6.5
23
7.0
2
7.5
9
8.0
20
8.5
7
9.0
6
9.5
pChEMBL
Approved Drugs

Approved Drugs

DRONEDARONE
CHEMBL184412
Approved 2009
CLEVIDIPINE
CHEMBL1237132
Approved 2008
TOLTERODINE
CHEMBL1382
Approved 1998
TROGLITAZONE
CHEMBL408
Approved 1997
NISOLDIPINE
CHEMBL1726
Approved 1995
AMLODIPINE
CHEMBL1491
Approved 1992
BEPRIDIL
CHEMBL1008
Approved 1990
NIMODIPINE
CHEMBL1428
Approved 1988
TERFENADINE
CHEMBL17157
Approved 1985
THIOPENTAL
CHEMBL441
Approved 1982
DILTIAZEM
CHEMBL23
Approved 1982
NIFEDIPINE
CHEMBL193
Approved 1981
VERAPAMIL
CHEMBL6966
Approved 1981
Assay Landscape

Assay Landscape

112
Total Assays
115
Tested Compounds
2
Assay Types
Functional — 103 assays, 79 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 88 64 5.7
tissue-based format 15 15 5.6
Binding — 9 assays, 115 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 4 92 6.4
tissue-based format 3 23 9.2
cell-based format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine